Intravenous iron exposure and mortality in patients on hemodialysis

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 11, 2015, Pages 1930-1939

  Miskulin, Dana C ^a   Tangri, Navdeep ^a   Bandeen Roche, Karen ^a   Zhou, Jing ^a   McDermott, Aidan ^a   Meyer, Klemens B ^a   Ephraim, Patti L ^a   Michels, Wieneke M ^a   Jaar, Bernard G ^a   Crews, Deidra C ^a   Scialla, Julia J ^a   Sozio, Stephen M ^a   Shafi, Tariq ^a   Wu, Albert W ^a   Cook, Courtney ^a   Boulware, L Ebony ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

IRON; FERRITIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EXPOSURE; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; INFECTION; INFORMATION PROCESSING; IRON METABOLISM DISORDER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; RISK ASSESSMENT; ADVERSE EFFECTS; BLOOD; EPIDEMIOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE, CHRONIC; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY; TIME; UNITED STATES;

ADMINISTRATION, INTRAVENOUS; CARDIOVASCULAR DISEASES; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HUMANS; INFECTION; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; TIME FACTORS; UNITED STATES;

EID: 84926442768     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03370414     Document Type: Article

References (49)

1. Fuller DS, Pisoni RL, Bieber BA, Gillespie BW, Robinson BM: The DOPPS Practice Monitor for US dialysis care: Trends through December 2011. Am J Kidney Dis 61: 342–346, 2013
2. FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm. Accessed July 2, 2012
3. The Federal Register 42 CFR Parts 410, 413 and 414 Medicare Program; End-Stage Renal Disease Prospective Payment System; Final Rule and Proposed Rule. Available at: http://www.gpo.gov/fdsys/pkg/FR-2010-08-12/pdf/2010-18466.pdf. Accessed July 2, 2013
4. Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, Van Landuyt HW: Iron overload in haemodialysis patients increases the risk of bacteraemia: A prospective study. Nephrol Dial Transplant 5: 130–134, 1990
5. Payne SM: Iron and virulence in the family Enterobacteriaceae. Crit Rev Microbiol 16: 81–111, 1988
6. Seifert A, von Herrath D, Schaefer K: Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 65: 1015–1024, 1987
7. Sunder-Plassmann G, Patruta SI, Ho¨ rl WH: Pathobiology of the role of iron in infection. Am J Kidney Dis 34[Suppl 2]: S25–S29, 1999
8. Drȕeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212–2217, 2002
9. Kuo K-L, Hung S-C, Lin Y-P, Tang C-F, Lee T-S, Lin C-P, Tarng DC: Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS ONE 7: e50295, 2012
10. Reis KA, Guz G, Ozdemir H, Erten Y, Atalay V, Bicik Z, Ozkurt ZN, Bali M, Sindel S: Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J 46: 255–264, 2005
11. Rooyakkers TM, Stroes ES, Kooistra MP, van Faassen EE, Hider RC, Rabelink TJ, Marx JJ: Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32[Suppl 1]: 9–16, 2002
12. Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, St Pierre TG, Olynyk JK: Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 6: 77–83, 2011
13. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Janklewicz P, Drahi G, Dahan H, Cohen Y: Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: A MRI study. Am J Med 125: 991–999, 2012
14. Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, Martina G, Piga A: Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 65: 1091–1098, 2004
15. Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV: Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J AmSoc Nephrol 24: 1151–1158, 2013
16. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, FaichG: Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15: 1623–1632, 2004
17. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G: Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13: 734–744, 2002
18. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG: Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16: 3070– 3080, 2005
19. Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA: Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS ONE 8: e78930, 2013
20. Boulware LE, Tangri N, Ephraim PL, Scialla JJ, Sozio SM, Crews DC, Shafi T, Miskulin DC, Liu J, St Peter W, Jaar BG, Wu AW, Powe NR, Navaneethan SD, Bandeen-Roche K; DEcIDE ESRD Patient Outcomes in Renal Disease Study Investigators: Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: The DEcIDE patient outcomes in end stage renal disease study. BMC Nephrol 13: 167–177, 2012
21. Miskulin DC, Zhou J, Tangri N, Bandeen-Roche K, Cook C, Ephraim PL, Crews DC, Scialla JJ, Sozio SM, Shafi T, Jaar BG, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators: Trends in anemia management in US hemodialysis patients 2004-2010. BMC Nephrol 14: 264, 2013
22. Liu J, Huang Z, Gilbertson DT, Foley RN, Collins AJ: An improved comorbidity index for outcome analyses among dialysis patients. Kidney Int 77: 141–151, 2010
23. Hernán MA, Brumback B, Robins JM: Marginal structural models to estimate the causal effect of zidovudine on the survival of HIVpositive men. Epidemiology 11: 561–570, 2000
24. Robins JM, Hernan MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550–560, 2000
25. Prentice RL, Gloeckler LA: Regression analysis of grouped survival data with application to breast cancer data. Biometrics 34: 57–67, 1978
26. Liang K-Y, Zeger SL: Longitudinal data analysis using generalized linear models. Biometrika 73: 13–22, 1986
27. Litton E, Xiao J, Ho KM: Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomised clinical trials. BMJ 347: f4822, 2013
28. Monson R: Occupational Epidemiology, 2nd Ed., Boca Raton, FL, CRC Press Inc., 1990
29. Sargent JA, Acchiardo SR: Iron requirements in hemodialysis. Blood Purif 22: 112–123, 2004
30. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2: 295–296, 2012
31. Besarab A, Kaiser JW, Frinak S: A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 34: 21–28, 1999
32. Chang CH, Chang CC, Chiang SS: Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol 57: 136–141, 2002
33. DeVita MV, Frumkin D, Mittal S, Kamran A, Fishbane S, Michelis MF: Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 60: 335–340, 2003
34. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26: 41–46, 1995
35. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694–1699, 1996
36. Sunder-Plassmann G, Horl WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10: 2070–2076, 1995
37. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR; DRIVE Study Group: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients’ Response to IV Ironwith Elevated Ferritin (DRIVE) Study. J AmSoc Nephrol 18: 975–984, 2007
38. Kapoian T, O’Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19: 372–379, 2008
39. Injection Epogen (Recombinant Epoetin Alpha) Prescribing Information. Available at: http://www.epogen.com/. Accessed July 11, 2014
40. Unger EF, Thompson AM, Blank MJ, Temple R: Erythropoiesisstimulating agents—time for a reevaluation. N Engl J Med 362: 189–192, 2010
41. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791–798, 2008
42. Dallman PR: Biochemical basis for the manifestations of iron deficiency. Annu Rev Nutr 6: 13–40, 1986
43. Dallman PR, Schwartz HC: Myoglobin and cytochrome response during repair of iron deficiency in the rat. J Clin Invest 44: 1631–1638, 1965
44. Dong F, Zhang X, Culver B, Chew HG Jr., Kelley RO, Ren J: Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: Involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 109: 277–286, 2005
45. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan B-A, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361: 2436–2448, 2009
46. Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Luscher TF, Mori C, Willenheimer R, Ponikowski P, Anker SD: The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: A subanalysis of the FAIR-HF study. Eur Heart J 34: 30–38, 2013
47. Koo HM, Kim CH, Doh FM, Lee MJ, Kim EJ, Han JH, Han JS, Oh HJ, Park JT, Han SH, Yoo T-H, Kang S-W: The relationship of initial transferrin saturation to cardiovascular parameters and outcomes in patients initiating dialysis. PLoS ONE 9: e87231, 2014
48. Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, Kalantar-Zadeh K: Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 52: 727–736, 2008
49. USRDS: Assessment of the new bundled dialysis payment system and overview of the ESRD program. Presented at the Annual Meeting of the American Society of Nephrology, San Diego, CA, October 30-November 4, 2012